Innovent Agreement was Bolt Biotherapeutics’s largest revenue line in fiscal 2023, bringing in $4.10M of $7.80M (53%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2022 | FY 2023 |
|---|---|---|
| Genmab Agreement | $4.20M | $3.70M |
| Innovent Agreement | $1.50M | $4.10M |
| Total | $5.70M | $7.80M |
Bolt Biotherapeutics brought in $7.80M from its two revenue lines in fiscal 2023, the year ended December 31, 2023. That was up 36.8% from $5.70M in fiscal 2022. Innovent Agreement was the largest at $4.10M (52.6%), ahead of Genmab Agreement at $3.70M (47.4%).
Compared with fiscal 2022, Innovent Agreement grew 173.3% to $4.10M, while Genmab Agreement fell 11.9% to $3.70M.
Bolt Biotherapeutics (BOLT) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2023, Innovent Agreement was its largest revenue line, bringing in $4.10M (52.6% of the total), followed by Genmab Agreement at $3.70M (47.4%).
Innovent Agreement was Bolt Biotherapeutics' largest revenue line in fiscal 2023, bringing in $4.10M, or 52.6% of the $7.80M total across its two revenue lines.
Innovent Agreement grew faster than Genmab Agreement in fiscal 2023, up 173.3% from $1.50M to $4.10M. Genmab Agreement fell 11.9% to $3.70M.
Every figure comes from Bolt Biotherapeutics' annual financial filings, as reported. Each line keeps the name Bolt Biotherapeutics gives it, and years follow its fiscal calendar.
Bolt Biotherapeutics' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2022, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.